10-Q: Cardiff Oncology Reports First Quarter 2024 Financial Results and Clinical Trial Updates

Cardiff Oncology's first quarter 2024 results show a net loss of $10.0 million, with ongoing clinical trial advancements and a focus on their lead drug candidate, onvansertib.

Summary

• Cardiff Oncology reported a net loss of $10.0 million for the first quarter of 2024, compared to a net loss of $11.2 million for the same period in 2023.
• The company's royalty revenues increased to $205,000 from $83,000 year-over-year.
• Research and development expenses decreased to $8.0 million from $9.1 million year-over-year, primarily due to reduced chemistry, manufacturing and control costs.
• Selling, general and administrative expenses increased slightly to $3.13 million from $3.08 million year-over-year.
• As of March 31, 2024, Cardiff Oncology had $67.2 million in cash, cash equivalents, and short-term investments.
• The company believes it has sufficient cash to meet its funding requirements for at least the next 12 months.
• Cardiff Oncology is advancing its clinical programs for onvansertib, including a Phase 2 trial in first-line RAS-mutated metastatic colorectal cancer (mCRC) and investigator-initiated trials in other cancers.
• The company expects to release initial data from the CRDF-004 trial in the second half of 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments in clinical trials and a decrease in net loss, the company is still operating at a loss and requires additional funding, which introduces uncertainty. The sentiment is neutral to slightly negative due to the ongoing financial challenges.

Positives

• The company's net loss decreased year-over-year, indicating improved financial performance.
• Royalty revenues more than doubled compared to the same period last year.
• Research and development expenses decreased, suggesting improved cost management.
• The company has a strong cash position of $67.2 million, providing a financial runway for at least the next 12 months.
• The first patient was dosed in the CRDF-004 trial, marking a significant milestone in the company's clinical development program.
• The company is actively pursuing multiple clinical trials across various cancer indications.

Negatives

• The company continues to incur net losses, with a $10.0 million loss in Q1 2024.
• The company is reliant on additional capital to further advance its clinical trial programs and support operations.
• The company's operating cash flow remains negative.
• The company's drug development efforts are in their early stages, with no guarantee of success.

Risks

• The company's ability to raise additional capital is uncertain, and any equity financing could dilute existing shareholders.
• The company's clinical trials may not be successful, and the company may not receive regulatory approval for its drug candidates.
• The company faces competition from other biotechnology companies developing cancer therapies.
• The company's drug development efforts are subject to inherent uncertainties, including long clinical testing durations and regulatory approval cycles.
• The company's future success depends on the successful development and commercialization of its drug candidates.

Future Outlook

Cardiff Oncology expects to release initial data from the CRDF-004 trial in the second half of 2024 and believes its current capital resources are sufficient to fund operations into the third quarter of 2025. The company anticipates continuing to incur losses and will require additional capital to advance its clinical programs.

Management Comments

• Management believes the company has sufficient cash to meet its funding requirements for at least the next 12 months.
• Management expects to continue to incur losses and require additional capital to further advance its clinical trial programs and support its other operations.

Industry Context

Cardiff Oncology is operating in the competitive biotechnology sector, focusing on oncology therapeutics. The company's approach of combining onvansertib with standard of care treatments aligns with the industry trend of exploring combination therapies to improve patient outcomes. The company's focus on specific cancer types and genetic mutations is also a common strategy in the precision medicine space.

Comparison to Industry Standards

• The reported 19% objective response rate (ORR) in the mPDAC trial compares favorably to the historical control of 7.7% in the second-line setting, suggesting a potential improvement over standard of care.
• The median progression-free survival (mPFS) of 5.0 months in the mPDAC trial also exceeds the historical control of 3.1 months with standard of care.
• The 29% ORR observed in the TROV-054 trial for KRAS-mutated mCRC is higher than the 5-13% ORR seen in historical control trials of different drug combinations.
• The mPFS of 9.3 months in the TROV-054 trial is also longer than the ~4.5-6.7 months seen in historical control trials.
• The company's focus on specific genetic mutations, such as RAS-mutated mCRC, is consistent with the industry trend towards precision medicine, similar to companies like Amgen and Mirati Therapeutics who are also targeting specific mutations in cancer.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Employees are impacted by the company's financial performance and the progress of its clinical programs.
• Patients with cancer may benefit from the company's development of new therapies.
• Creditors are impacted by the company's financial stability and ability to repay debts.
• Suppliers are impacted by the company's ability to pay for goods and services.

Next Steps

• The company plans to release initial data from the CRDF-004 trial in the second half of 2024.
• The company plans to initiate CRDF-005, a Phase 3, randomized trial with registrational intent, contingent upon the results of CRDF-004.
• The company will continue to enroll patients in its ongoing clinical trials.

Key Dates

Keywords

Cardiff Oncology, Onvansertib, PLK1 inhibitor, Metastatic colorectal cancer, mCRC, Pancreatic cancer, mPDAC, Small cell lung cancer, SCLC, Triple negative breast cancer, TNBC, Clinical trials, Biotechnology, Cancer therapy, RAS-mutated, FOLFIRI, FOLFOX, Bevacizumab